Werewolf Therapeutics (NASDAQ:HOWL) Posts Earnings Results, Misses Estimates By $0.03 EPS

Werewolf Therapeutics (NASDAQ:HOWL) issued its quarterly earnings data on Tuesday. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.03), Zacks reports. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.

Werewolf Therapeutics Price Performance

NASDAQ HOWL opened at $1.23 on Thursday. The company has a market cap of $54.81 million, a price-to-earnings ratio of -0.80 and a beta of 0.37. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. The stock’s fifty day moving average price is $1.37 and its 200 day moving average price is $1.82. Werewolf Therapeutics has a 1 year low of $1.03 and a 1 year high of $6.89.

Analyst Ratings Changes

Several brokerages recently issued reports on HOWL. Wedbush reaffirmed an “outperform” rating and set a $8.00 target price on shares of Werewolf Therapeutics in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Werewolf Therapeutics in a research note on Wednesday. Finally, JMP Securities decreased their price objective on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research report on Tuesday, January 14th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.